NCT00541242

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 586 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Conditions

• Ocular Hypertension
• Glaucoma

Interventions

Type	Name	Description
DRUG	bimatoprost 0.03% eye drops	Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
DRUG	latanoprost 0.005% eye drops	Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks

Timeline

• Start date: 2007-12-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2007-10-10
• Last updated: 2011-10-27
• Results posted: 2011-10-27

Locations

1 site across 1 country: United States